Literature DB >> 12535355

Hypomagnesemia after aneurysmal subarachnoid hemorrhage.

Walter M van den Bergh1, Ale Algra, Jan Willem Berkelbach van der Sprenkel, Cornelis A F Tulleken, Gabriël J E Rinkel.   

Abstract

OBJECTIVE: Hypomagnesemia frequently occurs in hospitalized patients, and it is associated with poor outcome. We assessed the frequency and time distribution of hypomagnesemia after aneurysmal subarachnoid hemorrhage (SAH) and its relationship to the severity of SAH, delayed cerebral ischemia (DCI), and outcome after 3 months.
METHODS: Serum magnesium was measured in 107 consecutive patients admitted within 48 hours after SAH. Hypomagnesemia (serum magnesium <0.70 mmol/L) at admission was related to clinical and initial computed tomographic characteristics by means of the Mann-Whitney U test. Hypomagnesemia at admission and during the DCI onset period (Days 2-12) was related to the occurrence of DCI and hypomagnesemia at admission, and hypomagnesemia that occurred any time during the first 3 weeks after SAH was related to outcome.
RESULTS: Hypomagnesemia at admission was found in 41 patients (38%) and was associated with more cisternal (P = 0.006) and ventricular (P = 0.005) blood, a longer duration of unconsciousness (P = 0.007), and a worse World Federation of Neurosurgical Societies scale score at admission (P = 0.001). The crude hazard ratio for DCI with hypomagnesemia at admission was 2.4 (95% confidence interval, 1.0-5.6), and after multivariate adjustment it was 1.9 (95% confidence interval, 0.7-4.7). The hazard ratio of hypomagnesemia from Days 2 to 12 for patients with DCI was 3.2 (range, 1.1-8.9) after multivariate adjustment. The crude odds ratio for poor outcome (Glasgow Outcome Scale score, 1-3) with hypomagnesemia at admission was 2.5 (range, 1.1-5.5). Hypomagnesemia at admission did not contribute to the prediction of outcome in the multivariate model.
CONCLUSION: Hypomagnesemia is frequently present after SAH and is associated with severity of SAH. Hypomagnesemia occurring between Days 2 and 12 after SAH predicts DCI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535355     DOI: 10.1227/01.neu.0000043984.42487.0e

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  34 in total

1.  Is the magnesium era for aneurysmal subarachnoid hemorrhage over?

Authors:  Santiago Ortega-Gutierrez; Stephan A Mayer
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

Review 2.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Extracerebral organ dysfunction in the acute stage after aneurysmal subarachnoid hemorrhage.

Authors:  Wouter J Schuiling; Paul J W Dennesen; Gabriël J E Rinkel
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Prevention of delayed cerebral ischaemia after subarachnoid haemorrhage.

Authors:  R Al-Shahi; M Robson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12       Impact factor: 10.154

Review 5.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Low Serum Calcium and Magnesium Levels and Rupture of Intracranial Aneurysms.

Authors:  Anil Can; Robert F Rudy; Victor M Castro; Dmitriy Dligach; Sean Finan; Sheng Yu; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du
Journal:  Stroke       Date:  2018-05-29       Impact factor: 7.914

Review 7.  Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  M Kamran Athar; Joshua M Levine
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 8.  Current management of delayed cerebral ischemia: update from results of recent clinical trials.

Authors:  Shakira Brathwaite; R Loch Macdonald
Journal:  Transl Stroke Res       Date:  2013-12-13       Impact factor: 6.829

9.  Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage.

Authors:  Diego Castanares-Zapatero; Philippe Hantson
Journal:  Ann Intensive Care       Date:  2011-05-24       Impact factor: 6.925

10.  Ventricular arrhythmia risk after subarachnoid hemorrhage.

Authors:  J Michael Frangiskakis; Marilyn Hravnak; Elizabeth A Crago; Masaki Tanabe; Kevin E Kip; John Gorcsan; Michael B Horowitz; Amin B Kassam; Barry London
Journal:  Neurocrit Care       Date:  2009-01-28       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.